List of Fetzima drug patents

Fetzima is owned by Allergan.

Fetzima contains Levomilnacipran Hydrochloride.

Fetzima has a total of 3 drug patents out of which 0 drug patents have expired.

Fetzima was authorised for market use on 25 July, 2013.

Fetzima is available in capsule, extended release;oral dosage forms.

Fetzima can be used as treatment of major depressive disorder (mdd).

The generics of Fetzima are possible to be released after 23 May, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8865937 ALLERGAN Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43879 ALLERGAN Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Jan, 2026

(2 years from now)

US8481598 ALLERGAN Stable dosage forms of levomilnacipran
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Oct 7, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)


How can I launch a generic of FETZIMA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in